Anxiety Disorders, Sleep Disorder
Conditions
Keywords
Adaptogen
Brief summary
This study aims to examine the effectiveness of Adaptogen Elixir herbal drink in relieving emotions and improving sleep quality. Participants will be randomly assigned to either the placebo group or the Adaptogen Elixir herbal drink group, with 25 participants in each group. On the day of the experiment (week 0), participants are required to collect blood and saliva samples, fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions. Subsequently, participants will be given the experimental samples and instructed to consume them continuously for 4 weeks following the instruction. Follow-up assessments will be conducted in the 2nd and 4th weeks, participants are required to collect blood and saliva samples, fill out questionnaires assessing sleep disorders and stress condition, and use a sleep monitoring system to track their sleep and autonomic nervous system conditions.
Interventions
DIETARY_SUPPLEMENTPlacebo drink
consume 1 drink per day for 4 weeks
DIETARY_SUPPLEMENTAdaptogen Elixir drink
consume 1 drink per day for 4 weeks
Sponsors
TCI Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Adults aged above 18 years old. * Individuals experiencing insomnia issues (PSQI \> 5) or high levels of anxiety (GAD-7 \> 9). * No medication use or regular use of sleeping pills or antidepressants in the past month. * No ongoing mental illnesses. * No ongoing physical illnesses. * No other sleep disorders. * No circadian rhythm issues. * No consumption of sleep or stress-related supplements in the past month.
Exclusion criteria
* Pregnant or breastfeeding women. * Individuals with significant organic diseases such as organ transplants, epilepsy or seizures, liver or kidney diseases, malignant tumors, endocrine disorders, or a history of alcohol or substance use disorders. * Individuals known to be allergic to any components of the product.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sleep monitoring | Week 0 (Baseline), Week 2, Week 4 | The difference of electrocardiosignal between two specific points on the body surface will be used to reflect sleep state. |
| Sleeping qualityy | Week 0 (Baseline), Week 2, Week 4 | The Pittsburgh Sleep Quality Index (PSQI) will be utilized to assess sleeping quality. The minimum value is 0, the maximum value is 42. The higher the score, the worse the outcome. |
| Sleeping disorders | Week 0 (Baseline), Week 2, Week 4 | Insomnia Severity Index (ISI) will be utilized to assess sleeping disorders. The minimum value is 0, the maximum value is 28. The higher the score, the worse the outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Neuropeptide Y concentration | Week 0 (Baseline), Week 2, Week 4 | Venous blood samples will be collected to measure concentrations of Neuropeptide Y. |
| Low Frequency/High Frequence (LF/HF) ratio | Week 0 (Baseline), Week 2, Week 4 | A sleep monitoring system will be utilized to measure LF/HF ratio |
| Cortisol concentration | Week 0 (Baseline), Week 2, Week 4 | Saliva samples will be collected to measure concentrations of cortisol. |
| Anxiety | Week 0 (Baseline), Week 2, Week 4 | Generalized Anxiety Disorder-7 (GAD-7) will be utilized to assess anxiety. The minimum value is 0, the maximum value is 21. The higher the score, the worse the outcome. |
Countries
Taiwan
Outcome results
None listed